Photopolymerizable Hydrogel for Enhanced Intramyocardial Vascular Progenitor Cell Delivery and Post‐Myocardial Infarction Healing
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202301581 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Xuechong Hong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, Boston Children's Hospital, Boston, MA, 02115, USA. Hauptthemen laut MEDLINE: Hydrogels, Myocardial Infarction. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NHLBI NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
Cell transplantation success for myocardial infarction (MI) treatment is often hindered by low engraftment due to washout effects during myocardial contraction. A clinically viable biomaterial that enhances cell retention can optimize intramyocardial cell delivery. In this study, a therapeutic cell delivery method is developed for MI treatment utilizing a photocrosslinkable gelatin methacryloyl (GelMA) hydrogel. Human vascular progenitor cells, capable of forming functional vasculatures upon transplantation, are combined with an in situ photopolymerization approach and injected into the infarcted zones of mouse hearts. This strategy substantially improves acute cell retention and promotes long‐term post‐MI cardiac healing, including stabilized cardiac functions, preserved viable myocardium, and reduced cardiac fibrosis. Additionally, engrafted vascular cells polarize recruited bone marrow‐derived neutrophils toward a non‐inflammatory phenotype via transforming growth factor beta (TGFβ) signaling, fostering a pro‐regenerative microenvironment. Neutrophil depletion negates the therapeutic benefits generated by cell delivery in ischemic hearts, highlighting the essential role of non‐inflammatory, pro‐regenerative neutrophils in cardiac remodeling. In conclusion, this GelMA hydrogel‐based intramyocardial vascular cell delivery approach holds promise for enhancing the treatment of acute myocardial infarction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiac Surgery, Boston Children's Hospital, Boston, MA, 02115, USA.
- Department of Surgery, Harvard Medical School, Boston, MA, 02115, USA.
- Department of Lymphoma and Myeloma, The University of Texas, M. D. Anderson Cancer Center, Houston, TX, 77030, USA.
- Harvard Stem Cell Institute, Harvard University, Cambridge, MA, 02138, USA.
ORCID-Profile: Juan M Melero-Martin
Förderung
- NIH HHS
- NHLBI NIH HHS
- NIAMS NIH HHS
- National Institutes of Health
Zitieren
APA
Hong, X., Luo, A. C., Doulamis, I., Oh, N., Im, G. B., Lin, C. Y., Del Nido, P. J., Lin, R. Z., & Melero-Martin, J. M. (2023). Photopolymerizable Hydrogel for Enhanced Intramyocardial Vascular Progenitor Cell Delivery and Post‐Myocardial Infarction Healing. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202301581
Vancouver
Hong X, Luo AC, Doulamis I, Oh N, Im GB, Lin CY, et al. Photopolymerizable Hydrogel for Enhanced Intramyocardial Vascular Progenitor Cell Delivery and Post‐Myocardial Infarction Healing. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202301581
BibTeX
@article{Hong2023,
author = {Hong, Xuechong and Luo, Allen Chilun and Doulamis, Ilias and Oh, Nicholas and Im, Gwang-Bum and Lin, Chun-Yen and Del Nido, Pedro J and Lin, Ruei-Zeng and Melero-Martin, Juan M},
title = {Photopolymerizable Hydrogel for Enhanced Intramyocardial Vascular Progenitor Cell Delivery and Post‐Myocardial Infarction Healing},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202301581}
}
EUVIMED